*.*

Source link : https://www.newshealth.biz/health-news/izokibep-marches-on-for-psoriatic-arthritis/

VIENNA — Preliminary results with the investigational interleukin-17A (IL-17A) inhibitor izokibep in a phase IIb/III trial for psoriatic arthritis (PsA) built on earlier positive findings, potentially paving the way toward final approval. After 16 weeks of treatment in the randomized, placebo-controlled study, 40% and 43% of patients receiving 160 mg of izokibep weekly or biweekly, […]

Author : News Health

Publish date : 2024-06-16 13:38:19

Copyright for syndicated content belongs to the linked Source.

........
....................................................................................................